JP2024522949A5 - - Google Patents

Info

Publication number
JP2024522949A5
JP2024522949A5 JP2023563256A JP2023563256A JP2024522949A5 JP 2024522949 A5 JP2024522949 A5 JP 2024522949A5 JP 2023563256 A JP2023563256 A JP 2023563256A JP 2023563256 A JP2023563256 A JP 2023563256A JP 2024522949 A5 JP2024522949 A5 JP 2024522949A5
Authority
JP
Japan
Prior art keywords
chimeric protein
protein complex
cells
modified
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023563256A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522949A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/025143 external-priority patent/WO2022221746A1/en
Publication of JP2024522949A publication Critical patent/JP2024522949A/ja
Publication of JP2024522949A5 publication Critical patent/JP2024522949A5/ja
Pending legal-status Critical Current

Links

JP2023563256A 2021-04-16 2022-04-16 Ｉｌ－２系構築物 Pending JP2024522949A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163175827P 2021-04-16 2021-04-16
US63/175,827 2021-04-16
US202263297330P 2022-01-07 2022-01-07
US63/297,330 2022-01-07
PCT/US2022/025143 WO2022221746A1 (en) 2021-04-16 2022-04-16 Il-2 based constructs

Publications (2)

Publication Number Publication Date
JP2024522949A JP2024522949A (ja) 2024-06-24
JP2024522949A5 true JP2024522949A5 (enExample) 2025-04-23

Family

ID=83639788

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023563256A Pending JP2024522949A (ja) 2021-04-16 2022-04-16 Ｉｌ－２系構築物

Country Status (9)

Country Link
US (1) US20240199714A1 (enExample)
EP (1) EP4323392A4 (enExample)
JP (1) JP2024522949A (enExample)
KR (1) KR20240021155A (enExample)
AU (1) AU2022258840A1 (enExample)
CA (1) CA3215204A1 (enExample)
IL (1) IL307574A (enExample)
MX (1) MX2023012131A (enExample)
WO (1) WO2022221746A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
CA3165927A1 (en) 2020-01-11 2021-07-15 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
EP4626486A2 (en) * 2022-11-30 2025-10-08 The Regents of University of California Multispecific engineered biomolecules and uses thereof
WO2024119193A2 (en) * 2022-12-02 2024-06-06 AskGene Pharma, Inc. Mutant il-2 polypeptides and il-2 prodrugs
WO2026015864A1 (en) * 2024-07-12 2026-01-15 Outpace Bio, Inc. Cd8 binding polypeptides and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6955807B1 (en) * 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
AU2015301936B2 (en) * 2014-08-11 2019-03-07 Delinia, Inc. Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases
CR20170510A (es) * 2015-04-10 2018-02-26 Amgen Inc Muteínas de interuquina 2 para la expansión de células t regulatorias
JP7422480B2 (ja) * 2016-05-04 2024-01-26 アムジエン・インコーポレーテツド 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質
EP3538548A4 (en) * 2016-11-08 2020-08-19 Delinia, Inc. IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
JP7148539B2 (ja) * 2017-04-03 2022-10-05 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 免疫抱合体
US10676516B2 (en) * 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
KR102777151B1 (ko) * 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
PE20210313A1 (es) * 2018-03-28 2021-02-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
KR20210005872A (ko) * 2018-03-28 2021-01-15 오리오니스 바이오사이언시즈 인코포레이티드 이작용성 단백질 및 이의 작제물
KR20250156190A (ko) * 2018-06-22 2025-10-31 큐진 인크. 인터루킨-2 변이체 및 이의 사용 방법
EP3980051A4 (en) * 2019-06-05 2023-09-13 Asher Biotherapeutics, Inc. FUSIONS OF MUTANT INTERLEUKIN-2 POLYPEPTIDES WITH ANTIGEN-BINDING MOLECULES TO MODULATE THE FUNCTION OF IMMUNE CELLS
WO2020252421A2 (en) * 2019-06-14 2020-12-17 Cugene, Inc. Novel interleukin-2 variants and bifunctional fusion molecules thereof

Similar Documents

Publication Publication Date Title
JP2024522949A5 (enExample)
Jin et al. Emerging new therapeutic antibody derivatives for cancer treatment
Tapia-Galisteo et al. When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy
US11357826B2 (en) IL-10 EGFR antibody fusion protein and uses thereof
JP6997743B2 (ja) Ｐｄ－１に結合する抗原結合蛋白質
Strohl Current progress in innovative engineered antibodies
RU2018139339A (ru) Новые биспецифические полипептиды против cd137
JP2019523630A5 (enExample)
JP2022534837A5 (enExample)
JP2021531754A5 (enExample)
JP2020506727A5 (enExample)
JP2020530298A5 (enExample)
CN105431205B (zh) 抑制肿瘤转移的IgE抗体
JP2023546725A5 (enExample)
JP2022512891A5 (enExample)
Ahmed et al. Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody
US20230235011A1 (en) Fc-cd80 fusion protein and conjugates thereof and their uses
CN112930357A (zh) B7-h7结合剂及其使用方法
Geng et al. Anti-PD-L1-based bispecific antibodies targeting co-inhibitory and co-stimulatory molecules for cancer immunotherapy
JP2022550345A5 (enExample)
US12215164B2 (en) Immunotoxins with albumin binding domain
TW202430553A (zh) Psma抗體及其用途
Wang et al. Maximizing activity and selectivity of antibody-mediated effector functions using antibody mixtures
US20250326813A1 (en) Engineered interleukin-2 receptor beta reduced-binding agonist
Zhu et al. Highlights of antibody engineering and therapeutics 2019 in San Diego, USA: bispecific antibody design and clinical applications